Sobi to buy Dova Pharmaceuticals in £915m deal

This article was originally published here

The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals

The post Sobi to buy Dova Pharmaceuticals in £915m deal appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply